Next Article in Journal
Predictors of Recurrent Laboratory-Confirmed Symptomatic SARS-CoV-2 Infections in a Cohort of Healthcare Workers
Next Article in Special Issue
Assessing COVID-19 Vaccine Booster Hesitancy Using the Modified 5C Scale in Zhejiang Province, China: A Cross-Sectional Study
Previous Article in Journal
Development and Evaluation of Recombinant B-Cell Multi-Epitopes of PDHA1 and GAPDH as Subunit Vaccines against Streptococcus iniae Infection in Flounder (Paralichthys olivaceus)
Previous Article in Special Issue
Vaccinated Yet Booster-Hesitant: Perspectives from Boosted, Non-Boosted, and Unvaccinated Individuals
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Epidemiology of the Acceptance of Anti COVID-19 Vaccine in Urban and Rural Settings in Cameroon

by
Cecile Ingrid Djuikoue
1,2,3,*,
Rodrigue Kamga Wouambo
2,3,4,*,
Majeste Mbiada Pahane
5,†,
Blaise Demanou Fenkeng
6,†,
Cedric Seugnou Nana
1,2,†,
Joelle Djamfa Nzenya
1,2,
Flore Fotso Kamgne
6,
Cedric Ngalani Toutcho
1,2,
Benjamin D. Thumamo Pokam
7 and
Teke Apalata
8
1
Department of Public Health, Faculty of Health Sciences, Université des Montagnes, Bangangte BP 208, Cameroon
2
Foundation Prevention and Control, Bangangte BP 208, Cameroon
3
American Association of Microbiology (ASM), ASM Cameroon, Bangangte P.O. Box 222, Cameroon
4
Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, University of Leipzig, 04109 Leipzig, Germany
5
Institute of Fisheries and Aquatic Sciences, University of Douala, Douala P.O. Box 24157, Cameroon
6
Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala Box 24157, Cameroon
7
Faculty of Health Sciences, University of Buea, Buea P.O. Box 24157, Cameroon
8
Faculty of Health Sciences, Walter Sisulu University, Mthatha 5117, South Africa
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Vaccines 2023, 11(3), 625; https://doi.org/10.3390/vaccines11030625
Submission received: 3 February 2023 / Revised: 3 March 2023 / Accepted: 6 March 2023 / Published: 10 March 2023

Abstract

:
The COVID-19 pandemic rapidly evolved in December 2019 and to prevent its spread, effective vaccines were produced and made available to the population. Despite their availability so far in Cameroon, the vaccination coverage remains low. This study aimed at describing the epidemiology of the acceptance of vaccines against COVID-19 in some urban and rural areas of Cameroon. A cross-sectional, descriptive and analytical survey was conducted from March 2021 to August 2021 targeting unvaccinated individuals from urban and rural area. After receiving appropriate administrative authorizations and an ethical clearance from the Institutional Review Board (or Ethics Committee) of Douala University (N° 3070CEI-Udo/05/2022/M), a cluster sampling at many degrees was performed and a language-adapted questionnaire was completed by each consenting participant. Data were analyzed using Epi info version 7.2.2.6 software and for p-values < 0.05, the difference was considered as statistically significant. Out of 1053 individuals, 58.02% (611/1053) participants were residing in urban and 41.98% (442/1053) in rural areas. Good knowledge relative to COVID-19 was significantly higher in urban areas as compared to rural areas (97.55% vs. 85.07, p < 0.000). The proportion of respondents who intended to accept the anti COVID-19 vaccine was significantly higher in urban areas than rural areas (42.55% vs. 33.26, p = 0.0047). Conversely, the proportion of anti COVID-19 reluctant respondents thinking that the vaccine can induce a disease was significantly higher in rural areas than urban areas (54 (35.07 vs. 8.84, p < 0.0001). The significant determinants of anti-COVID-19 acceptance were the level of education (p = 0.0001) and profession in the rural areas (p ≤ 0.0001), and only the profession (p = 0.0046) in the urban areas. This study globally showed that anti-COVID-19 vaccination remains a major challenge in urban as well as rural areas in Cameroon. We should continue sensitizing and educating the population about vaccine importance in preventing the COVID-19 spread.

1. Introduction

COVID-19 is an emerging viral infectious disease caused by the novel coronavirus 2 of the severe acute respiratory system, SARS-CoV 2. The WHO learned of its existence on 31 December 2020, when an outbreak of “viral pneumonia” cases was announced in the city of Wuhan, Hubei province in China [1]. On 30 January, the WHO declared the outbreak a public health emergency of international concern and then a pandemic the 11 March 2020 [2]. On 11 February, the WHO officially named the disease “coronavirus disease (COVID-19)” after germ isolation and molecular characterization on 7 January 2020 [2,3].
As of 27 November 2022, the world recorded 637 million confirmed cases and 6.6 million deaths globally [4]. In general, the United States of America (USA) represents so far the most affected country in the world with above 98,972,375 cases [4]. In Africa, COVID-19 affected all 47 African region countries with 8.887.814 cumulative cases, which represented around two percent of the infections around the world [5]. South Africa was the most drastically affected country, with more than 3.6 million infections, followed by Cameroon with 123,993 cases of COVID-19, of which 1965 died and over 2960 were cured [5].
In view of the rapid transmission capacity of this disease, unspecified interventions such as social distancing, barrier measures and quarantine can slow the spread of the virus and flatten the epidemic curve; however, the COVID-19 epidemic will only end if herd immunity is well established among the population, which is usually acquired through infection or vaccination. Although there have been barrier measures since the start of the pandemic, the morbidity rate is still increasing [6]. It is therefore urgent to find other effective strategies to overcome this disease. According to WHO, the COVID-19 vaccine remains the best weapon to effectively fight the pandemic. As of 23 December 2021, the WHO approved Oxford–AstraZeneca, Johnson and Johnson, Pfizer–BioNTech, Moderna, Sinopharm BIBP, CoronaVac, Janssen, Covaxin, and Novavax vaccines for emergency use worldwide including in low and middle income countries [7,8]. The COVID-19 Vaccines Global Access, abbreviated as COVAX, a worldwide initiative aimed at equitable access to COVID-19 vaccines, tests and therapies directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), alongside key delivery partner UNICEF, provided vaccines to the developing countries [9,10].
A study on COVID-19 vaccine hesitancy assessment among U.S. medical students conducted on 26 December 2020 was conducted; the majority of participants had positive attitudes towards vaccines and agreed that they would likely be exposed to COVID-19; however, only 53% indicated they would participate in a COVID-19 vaccine trial and 23% were unwilling to take a COVID-19 vaccine immediately [3]. Another study on vaccine reluctance in faculties of health sciences, dentistry and medicine at the University of Malta vis à vis to flu and the new COVID-19 vaccination on 12 November 2020 was made and revealed that the response rate was 23% (n = 852) [11]. The percentages of those who received the flu shot last year and will receive it this year have increased at all ages, highest for medicine and universities; for COVID-19 vaccination, little probable, undecided and likely to take were 30.5/25.3/44.02%, respectively. Concerns about the COVID-19 vaccination were related to insufficient knowledge about such a vaccine and potential long-term side effects [11]. Likewise, a study was conducted on the intention of nurses to accept the 2019 coronavirus disease vaccination and change in intention to accept the seasonal flu vaccination during the COVID-19 pandemic in China on the 21 October 2020. It revealed that most nurses went from refusing vaccination to hesitating or accepting than those who went accepting to hesitating or refusing. A total of 40% of participants intended to accept vaccination against COVID-19; these participants were in the private sector. Reasons for refusing and reluctance to take COVID-19 vaccination included “suspicion about efficacy, efficacy and safety”, “deem it unnecessary” and “no time to take it” [12].
Although Cameroon launched its vaccination efforts against COVID-19 in March 2021 with two type of vaccines (Sinopharm and AstraZeneca), only about 5% of the eligible population was vaccinated as of 18 November 2022, placing the country well behind the global target of achieving 70% vaccination coverage by the end of the year [13]. To close the vaccine equity gaps and achieve a broader population coverage goal by the end of the year, representatives from the WHO, UNICEF, GAVI, USAID and Africa CDC came together to advocate for top government leaders, and religious and civil society organizations on the need to support the Ministry of Public Health of Cameroon in its vaccination program against COVID-19 [13]. The anti COVID-19 vaccine acceptance is not shared by all social strata, negatively impacting its implementation. In Cameroon, the epidemiological data on the comparison between urban and rural areas concerning vaccine acceptance were scarce. This study was conducted prior the wide Cameroon’s national vaccination campaign to assess the new anti COVID-19 vaccine awareness in the urban and rural areas in order to contribute more efficiently for anti COVID-19 vaccine implementation.

2. Materials and Methods

2.1. Study Design, Location, Population and Period

A cross-sectional, descriptive and analytical study was carried out within a six-month period, from March 2021 to August 2021. Our sample was constituted essentially of ≥21 years old unvaccinated individuals residing in urban and rural areas in Cameroon.

2.2. Study Setting

A cluster sampling at many degrees was performed by randomly and successfully selecting two mains regions of Cameroon (Littoral and West regions). For that purpose, one populated city (urban area) and village (rural area) were included per region. In the littoral region, Douala (town) and Loum (village) were randomly selected, whereas it was Dschang (town) and Mbouda (village) for the west region. By definition, the choice of urban and rural areas per region was based on geography, population density, social amenities, infrastructure and education facilities and industrialization. In each town/village, streets were first randomly selected via pin through on the map, households were then randomly selected via systematic random sampling using dice throw for each street (the number revealed by the dice represented the number of households to jump between included ones) and a single adult or ≥18 years old individual was finally selected via simple random sampling in each household. Participants were interviewed on their socio-demographic characteristics, knowledge, social behaviors and thoughts relative to COVID-19 disease and vaccine using a structured, pretested and language-adapted questionnaire. All questionnaires with lack of information were excluded.

2.3. Data Management, Ethical Considerations

Data were compiled in an Excel spreadsheet and analyzed using Epi info 7.0 software (Center for Disease Control and Prevention, Atlanta, GA, USA) and considering a 95% confidence level. Figures were transposed into Excel 2016 spreadsheet. Percentages were compared using the chi-square test and logistic regression bivariate analyses were carried out with a considered margin of error of 5%. Thus, significant associations were considered when the p-value was less than or equal to 0.05.
An ethical approval from the institutional Ethics Committee of the University of Douala (N° 3070CEI-Udo/05/2022/M) and all subsequent administrative authorizations were obtained notably from the sub-divisional officers and mayors of the concerned towns and villages. Free and informed consent of respondents were obtained before each interview.

3. Results

3.1. Respondent Identification

Throughout this present study, 1056 individuals were included. However, three of them misfiled the questionnaire and were thus excluded. Among the 1053 respondents, 611 were residing in urban areas (396 in Douala and 208 in Dschang) and 442 in rural areas (215 in Loum and 234 in Mbouda). Table 1 summarises the distribution of respondents depending on their socio-demographic characteristics.
Table 1 shows that respondents of the group age < 30 years were the most represented 69.52% (732/1053), both in the urban and the rural areas. The mean age of the respondents was 29.30 ± 6.47 in urban and 28.95 ± 7.00 in rural. For the marital status, the sex, the profession, the single, the female sex and the profession with the resourceful ones represented the majority both in the rural and urban areas. In the two areas, the primary level and the Christian community were the greatest in both groups.

3.2. Knowledge of the Respondents on COVID-19 and Vaccination

Table 2 presents the distribution of respondents according to their knowledge.
Table 2 shows that the majority of respondents in the urban and rural areas knew about the existence of COVID-19 [97.55% (596/611) and 85.07% (376/422), respectively)], the existence of an anti-COVID-19 vaccine [97.22% (594/611) and 82.58% (365/422)], respectively)] and that this vaccine could be effective [68.09% (416/611) and 58.60% (259/442)], respectively)]. Nevertheless, the proportions were significantly higher in urban areas than rural areas. Similarly, the proportion of respondents who knew that we can be infected several times by COVID-19 was significantly greater in urban areas; 82.16% (502/611) than in rural areas; 36.65% (162/442). Table 2 also highlights the fact that fewer respondents in both urban and rural areas knew neither the highlighted modes of transmission of COVID-19 [31.26% (191/611) and 33.94% (15/442), respectively] nor the symptoms of this disease [4.91% (30/611) and 23.98% (106/442), respectively] and the possibility of recovery from COVID-19 without treatment [38.30% (234/611) and 28.05% (124/442), respectively]. It was observed that the percentage of respondents did not know COVID-19 symptoms was significantly lower in urban areas than in rural areas (p < 0.0001). Oppositely, the percentage of respondents who knew that there was a possibility of recovery from COVID-19 without treatment was significantly greater in urban areas compared to rural areas.

3.3. Acceptance of the COVID-19 Vaccine by the Populations

The distribution of respondents according to their acceptance of the COVID-19 vaccine is summarised in Table 3.
It appears from Table 3 that the majority both in the urban and the rural population were neutral for the reception of the COVID-19 vaccine [44.84% (274/611) and 51.58% (228/442), respectively]. Despite the relatively smaller percentage of respondents who agreed to accept anti-COVID-19 vaccine in both areas, it was significantly greater in the urban areas than in the rural areas (p = 0.0047). The most frequent reason for reluctance to anti COVID-19 vaccination was the fact that the vaccine may be not safe due to the speed of synthesis in both urban and rural areas (52.86% and 35.75%, respectively). Moreover, the reason based on the fact that the vaccine was to give a disease was significantly more frequent in rural areas (35.07%) than in urban areas (8.84%).

3.4. Determinants of Acceptance of Vaccination against COVID-19

Table 4 and Table 5 show the analysis of the probable associated factors to the acceptance of the anti-COVID-19 vaccine in univariate and multivariate logistic regression, respectively.
Overall, it appears from Table 4 that only the profession (trader) was associated with the acceptance of anti-COVID-19 vaccine acceptance in urban areas (p = 0.0046). Meanwhile, both the profession (trader) and the study level (Superior) were statistically associated with vaccine acceptance in rural areas [p < 0.0001 and p = 0.0001, respectively).
At this purpose, it was observed that the odds of being traders among respondents intending to accept anti-COVID-19 vaccine was, respectively, 0.54 folds and 0.21 folds the odds of being resourceful in urban and rural areas. Moreover, the odds of being at the superior educational level among respondents ready to accept anti-COVID-19 vaccine was 2.57 folds higher as compare to those with a null educational level.

4. Discussion

In order to contribute in the prevention and the control of the current COVID-19 pandemic and increase the adherence of the population to the vaccination, the present study was conducted in order to determine the epidemiology of the acceptance of vaccine against COVID-19 in Cameroon urban and rural areas. To carry out this study, we collected data with a structured, pretested and language adapted questionnaire.
Our sample consisted of 1053 individuals. From the applied methodology, it resulted that out of 1053 participants, a preponderance was noted toward females (84.81%), single respondents (61.73%), resourceful respondents (56.60%), primary level respondents (41.41%), and Christians (93.73%). This globally describes the most frequent socio-demographics in Cameroon. Moreover, we noticed more participants in urban than in rural area (611 vs. 442). A similar result was observed in a study conducted nationwide in Cameroon from 2020 to 2022 on factors driving COVID-19 vaccine hesitancy in Cameroon and their 9mplications for Africa, with 56.3% (3787/6732 from urban 43.7% vs. (2945/6732) from rural [14]. In contrast to urban settings, many people in rural areas were not really interested in such studies because of their misbelief, past history and lack of education [14]. Furthermore, the mean age of the respondents in this study was quite similar in both settings (29.30 ± 6.47 in urban and 28.95 ± 7.00 in rural) with subjects aged <30 years old (69.52%) most represented. A study conducted on gender and COVID-19 vaccine disparities in Cameroon reported quite a similar mean age of study participants, with participants aged <34 years most represented at 62.6% (153/249) [15]. In fact, as all African countries, Cameroon is made up of a young working population [16]. Additionally, as compared to young population, a higher reluctance to participate to the COVID-19 related activities was globally observed in older adults [16,17].
Despite the fact that the percentage of respondents who did not know COVID-19 symptoms were significantly lower in urban than in rural areas, the proportion of respondents aware of the existence of COVID-19 pandemic in contrast was globally high in both areas with slightly greater proportion in the urban area [97.55% (596/611) urban and 85.07% (376/422) rural]. This result was close to the one reported in the towns of Douala and Bangangté in 2020, where 71.6% declared that COVID-19 existed [18]. In fact, this was the result of cumulative efforts between WHO, non-government organisations, and governments including wide sensitization and financial support in response against the pandemic spread worldwide [19]. In addition, as COVID-19 evolved at the time of new technologies, the information about the deadly epidemic rapidly and widely spread through mass media, internet, from school or conferences and person to person.
In this study, 38.65% (407/1053) intended to accept anti-COVID-19 vaccine. This vaccine acceptance rate was relatively lower than that reported by the WHO (72.4%) [4], and Roman et al. (44.2%) [20], Lazarus et al. 79.1% [21]. Several factors could explain that relative low acceptance rate in our study such as mistrust of government and health authorities, concerns about vaccine safety and efficacy, some obstacles to effective vaccine science communication for lay audiences, public perceptions about that new COVID-19 variants can be possibly less severe, internet driven misinformation and fake news [22]. Of note, there were still a relative high proportions of the population who did not even believe neither in the existence of COVID-19 7.63% (81/1053) and anti-COVID vaccination 8.9%(94/1053) nor in the effectiveness of the vaccine 35.9%(378/1053). Taken together, all these data strengthened the need of a continuous education and sensitization of the population about the importance and safety of anti-COVID-19 vaccine nationwide.
Nevertheless, the anti-COVID vaccine acceptance rate was greater in urban than in rural areas (42.55% vs. 33.26%; p = 0.0047). These results were similar to those found in 2022 by Verena Barbieri et al. in Italy [23]. This similitude can be explained by the fact that reservations regarding COVID-19 vaccination strongly depend on the sociocultural characteristics of the study population. In addition to knowledge about the safety and efficacy of vaccines, fear of side effects, and level of information about the disease and vaccination, religious attitudes may play an important role in rural areas [24]. Reduced interest in information and a greater lack of trust in institutions and information sources among rural residents were also confirmed.
Upon the answers concerning the reason why they were not accepting the COVID-19 vaccine, the most represented answer was “the vaccine may not be safe/efficient enough regarding the rapid speed of synthesis and approval for emergence use by WHO”. Many studies, in line with our inquiry, already incriminated concerns about vaccine safety and efficacy as one of the major reason of vaccine hesitancy [21,22,25]. This can be explained by the fact that, intentional or not, misrepresentation and misinformation can derail progress in COVID-19 vaccination coverage, particularly if audiences choose not to seek COVID-19 information from official sources, such as WHO, the US Centers for Disease Control and Prevention or medical professional associations. These high-credibility sources of information face the additional challenges of pandemic fatigue or distress that may demotivate one to follow recommended protective behaviors and, among some communities, the challenge of low trust toward such institutions [26]. In fact, failure to convey clearly and consistently information to lay audiences during the current pandemic may have confused audiences, eroded confidence in the science and reduced vaccine acceptance [26]. With new technologies, self-digital health literacy through social media could have exacerbated this phenomenon [22].
Upon the completion of our study, the acceptance of anti-COVID-19 vaccine was significantly associated with the university level of education (p = 0.0001) in the rural area. This was obviously due to the easier aptitude to access good quality information, as a result of which the respondents were hence most aware on correct anti-COVID-19 vaccination issues [18]. Moreover, trader was the profession with the lowest rate of anti-COVID-19 vaccine acceptance in both urban and rural areas (p = 0.0046 and p < 0.0001, respectively). This result indicates the most reluctant socio-professional category to anti-COVID-19 vaccination campaigns. Nevertheless, basic reasons for this reluctance is still unknown, hence suggesting the initiation of researches targeting traders in urban and rural areas in order to better investigate this phenomenon. This can represent an important baseline to mitigate reluctance to anti-COVID-19 vaccination in a general issue.

5. Limitations

During this study, eligible participants in some household were skeptical and reluctant to participate due to misrepresentation and misinformation about COVID-19 and anti-COVID 19 vaccines. Moreover, since it was a face-to-face interview, eligible people absent from their household or who travelled abroad could not be reached during the survey period. Lastly, psychological patterns linked to vaccine hesitancy were general and non-specific, and thus, there is a need for more specific and further study on the subject.

6. Conclusions

This research showed that knowledge related to COVID-19 and its vaccine was better in urban areas compared to rural areas. Additionally, the acceptance intention was significantly more frequent in urban areas than in rural areas. Moreover, the significant determinants of anti-COVID-19 acceptance were the level of education and profession in the rural areas, and only the profession in the urban areas.

Author Contributions

Conceptualization, C.I.D.; data curation, C.I.D.; formal analysis, C.I.D. and R.K.W.; investigation, B.D.F., C.S.N., J.D.N., F.F.K. and C.N.T.; methodology, C.I.D. and B.D.T.P.; project administration, C.I.D., M.M.P., B.D.T.P. and T.A.; resources, C.I.D., B.D.F. and T.A.; software, C.I.D., C.S.N. and J.D.N.; supervision, T.A.; validation, C.I.D., R.K.W., C.N.T. and T.A.; visualization, C.I.D., R.K.W., M.M.P. and F.F.K.; writing—original draft, C.I.D. and J.D.N.; writing—review and editing, C.I.D., R.K.W., M.M.P., B.D.F., C.S.N., J.D.N., F.F.K., C.N.T., B.D.T.P. and T.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board (or Ethics Committee) of Douala University (N° 3070CEI-Udo/05/2022/M).

Informed Consent Statement

Informed consent was obtained from all participants involved in the study. Written informed consent was obtained from the patient(s) to publish this paper.

Data Availability Statement

All data are available upon request.

Acknowledgments

We gratefully thank all the participants who took part in this research.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Morens, D.M.; Daszak, P.; Taubenberger, J.K. Escaping Pandora’s box—Another novel coronavirus. N. Engl. J. Med. 2020, 382, 1293–1295. [Google Scholar] [CrossRef] [PubMed]
  2. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020, 395, 507–513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Victoria, C.L.; Arati, K.; Nelia, M.A. COVID-19 vaccine hesitancy among medical students. J. Public Health 2020, 43, 445–449. [Google Scholar] [CrossRef]
  4. WHO. Weekly Epidemiological Update on COVID-19—30 November 2022, Edition 120, 30 November 2022, Emergency Situational Updates. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2022 (accessed on 5 December 2022).
  5. WHO Africa, The Future of WHO COVID-19 Response Operations in Africa in 2022. Available online: https://www.afro.who.int/publications/future-who-covid-19-response-operations-africa-2022 (accessed on 5 December 2022).
  6. OMS. Novel Coronavirus (2019-nCoV) Situation Report-11. Available online: www.who.int (accessed on 31 January 2020).
  7. WHO. WHO Lists 9th COVID-19 Vaccine for Emergency Use with Aim to Increase Access to Vaccination in Lower-Income Countries. Geneva. 2021. Available online: https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries (accessed on 20 January 2023).
  8. Markus, H.; Hannah, K.; Simon, S.; Nadine, K. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280. [Google Scholar] [CrossRef]
  9. WHO. COVAX-Working for Global Equitable Access to COVID-19 Vaccines. Geneva. 2022. Available online: https://www.who.int/initiatives/act-accelerator/covax (accessed on 20 January 2023).
  10. Yu, Z.; Zixian, Z.; Yujia, W.; Yueqing, Z. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv 2020. [Google Scholar] [CrossRef] [Green Version]
  11. Grech, V.; Gauci, C. WITHDRAWN: Vaccine hesitancy in the University of Malta Faculties of Health Sciences, Dentistry and Medicine vis-à-vis influenza and novel COVID-19 vaccination. Early Hum. Dev. 2020, 12, 105258. [Google Scholar] [CrossRef] [PubMed]
  12. Wang, K.; Wong, E.; Ho, K.; Cheung, A.; Chan, E.; Yeoh, E.; Wong, S. Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey. Vaccine 2020, 38, 7049–7056. [Google Scholar] [CrossRef] [PubMed]
  13. Available online: https://www.who.int/news/item/11-12-2022-cameroon-steps-up-vaccination-efforts-with-support-from-who--unicef--wb-and-other-partners (accessed on 1 March 2023).
  14. Dinga, J.N.; Njoh, A.A.; Gamua, S.D.; Muki, S.E.; Titanji, V.P.K. Factors Driving COVID-19Vaccine Hesitancy in Cameroon and Their Implications for Africa: A Comparison of Two Cross-Sectional Studies Conducted 19 Months Apartin 2020 and 2022. Vaccines 2022, 10, 1401. [Google Scholar] [CrossRef] [PubMed]
  15. Amani, A.; Mossus, T.; Lekeumo Cheuyem, F.Z.; Bilounga, C.; Mikamb, P.; Basseguin Atchou, J.; Minyem Ngombi, A.P.; Nangmo, A.; Kamga, Y.; Bediang, G.; et al. Gender and COVID-19 Vaccine Disparities in Cameroon. COVID 2022, 2, 1715–1730. [Google Scholar] [CrossRef]
  16. Zhang, D.; Zhou, W.; Poon, P.K.; Kwok, K.O.; Chui, T.W.; Hung, P.H.Y.; Ting, B.Y.T.; Chan, D.C.; Wong, S.Y. Vaccine Resistance and Hesitancy among Older Adults Who Live Alone or Only with an Older Partner in Community in the Early Stage of the Fifth Wave of COVID-19 in Hong Kong. Vaccines 2022, 10, 1118. [Google Scholar] [CrossRef] [PubMed]
  17. Xiao, J.; Cheung, J.K.; Wu, P.; Ni, M.Y.; Cowling, B.J.; Liao, Q. Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: Serial cross-sectional surveys. Lancet Reg. Health West. Pac. 2022, 23, 100441. [Google Scholar] [CrossRef] [PubMed]
  18. Cécile, D.; Elodie, N.; Gildas, T. Knowledge, Attitudes and Practices of Populations Towards Barrier and Preventive Measures Against COVID-19 in Two Cities in Cameroon. World J. Public Health 2021, 6, 89–98. [Google Scholar] [CrossRef]
  19. Boum, Y.; Fai, K.; Nikolay, B.; Mboringong, A.; Bebell, L.; Ndifon, M.; Abbah, A.; Essaka, R.; Eteki, L.; Luquero, F.; et al. Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: A clinical, prospective, diagnostic accuracy study. Lancet Infect. Dis. 2021, 21, 1089–1096. [Google Scholar] [CrossRef] [PubMed]
  20. Roman, W.; Victor, M.; Corman, W.; Michael, S. Virological assessment of hospitalized patients with COVID-2019. Nature 2020, 581, 465–469. [Google Scholar] [CrossRef] [Green Version]
  21. Jeffrey, L.; Katarzyna, W.; Trenton, W.; Camila, P.; Lawrence, G.; Heidi, L.; Rabin, K.; Ratzan, S.C.; Kamarulzaman, A.; El-Mohandes, A. A Survey of COVID-19 Vaccine Acceptance across 23 Countries in 2022. Nat. Med. 2023, 29, 366–375. [Google Scholar] [CrossRef]
  22. Mohamed-Amine, C.; Sanchez-Ramirez, D.C.; Margriet, P.; Mohy, U.; Caroline, M.; Shabbir, S.-A. COVID-19 Infodemic and Digital Health Literacy in Vulnerable Populations: A Scoping Review. Digit. Health 2022, 8, 1–13. [Google Scholar] [CrossRef]
  23. Barbieri, V.; Wiedermann, C.J.; Lombardo, S.; Plagg, B.; Gärtner, T.; Ausserhofer, D.; Wiedermann, W.; Engl, A.; Piccoliori, G. Rural-Urban Disparities in Vaccine Hesitancy among Adults in South Tyrol, Italy. Vaccines 2022, 10, 1870. [Google Scholar] [CrossRef] [PubMed]
  24. Simanjorang, C.; Pangandaheng, N.; Tinungki, Y.; Medea, G. The determinants of SARS-CoV-2 vaccine hesitancy in a rural area of an Indonesia–Philippines border island: A mixed-method study. Enfermería Clínica (Engl. Ed.) 2022, 32, 376–384. [Google Scholar] [CrossRef] [PubMed]
  25. Sharma, R.; Jelly, P.; AS, V.; Chadha, L.; Saxena, V.; Mohan, L. A Comparative Study of Attitudes towards COVID-19 Vaccination in The Rural and Urban Population of Uttarakhand, India. J. Glob. Health Econ. Policy 2021, 1, e2021018. [Google Scholar] [CrossRef]
  26. Lazarus, J.; Ratzan, S.; Palayew, A.; Gostin, L.; Larson, H.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2021, 27, 225–228. [Google Scholar] [CrossRef] [PubMed]
Table 1. Distribution of respondents according to their socio-demographic characteristics.
Table 1. Distribution of respondents according to their socio-demographic characteristics.
VariablesUrban
(N = 611)
Rural Area
(N = 442)
p-Value
n (%)n (%)
Age
<30420 (68.74)312 (70.59)
[30.0–40.0]119 (19.80)85 (20.14)0.70
>4072 (11.46)45 (9.28)
Marital status
Single373 (61.05)277(62.67)
Divorced/Widow12 (1.96)3 (0.68)0.98
Married226 (36.99)162 (36.65)
Sex
Female519 (84.94)374 (84.62)0.97
Male92 (15.06)68 (15.38)
Profession
Trader119 (19.48)87 (19.68)
Student24 (3.93)64 (14.48)0.99
Resourceful *384 (62.85)212 (47.96)
Others *841 (3.75)79 (17.87)
Level of education
None64 (10.47)157 (35.52)
Primary271 (44.35)165 (37.33)0.87
Secondary99 (16.20)36 (8.14)
Superior177 (28.97)84 (19.00)
Religion
Animist2 (0.33)2 (0.45)
Christian574 (93.94)413 (93.44)0.93
Muslim35 (5.73)27 (6.11)
* Resourceful: Hustler, Person different from student or trader, without a full-time job and low income/month; others: teacher, taximen, housewife, driver, carpenter, etc.
Table 2. Distribution of respondents according to their knowledge on the existence and transmission routes of COVID-19.
Table 2. Distribution of respondents according to their knowledge on the existence and transmission routes of COVID-19.
VariablesUrban
(N = 611)
Rural
(N = 442)
p-Value
n (%)n (%)
COVID-19 exists
No15 (2.45)66 (14.93)
Yes596 (97.55)376 (85.07)<0.0001
Modes of transmission
No420 (68.74)292 (66.06)
Yes191 (31.26)150 (33.94)0.3602
Awareness of COVID-19 symptoms:
No581 (95.09)336 (76.02)
Yes30 (4.91)106 (23.98)<0.0001
We can recover from COVID-19 without treatment
No377 (61.70)318 (71.95)
Yes234 (38.30)124 (28.05)0.0005
We can be infected several times by COVID19
No109 (17.84)280 (63.35)
Yes502 (82.16)162 (36.65)<0.0001
There is a vaccine against COVID-19
No17 (2.78)77 (17.42)
Yes594 (97.22)365 (82.58)<0.0001
Anti COVID-19 Vaccination can be effective
No195 (31.91)183 (41.40)
Yes416 (68.09)259 (58.60)0.0016
Table 3. Distribution of the respondents according of anti-COVID-19 vaccine.
Table 3. Distribution of the respondents according of anti-COVID-19 vaccine.
VariablesUrban (N = 611)Rural (N = 442)p-Value
n (%)n (%)
Would you agree to receive COVID-19 vaccine?
Neutral274 (44.84)228 (51.58)Ref
Agree260 (42.55)147 (33.26)0.0047
Disagree77 (12.60)67 (15.16)0.8137
Reasons for not accepting the COVID-19 vaccine
It is a negligible threat disease and can be cured48 (7.86)27 (6.11)Ref
I do not have enough information about the vaccine186 (30.44)102 (23.08)0.9251
It is to give us a disease54 (8.84)155 (35.07)<0.0001
The vaccine may be not safe due to the speed of synthesis323 (52.86)158 (35.75)0.5902
Table 4. Factors to acceptance of the vaccine against COVID-19 in a univariate logistic regression.
Table 4. Factors to acceptance of the vaccine against COVID-19 in a univariate logistic regression.
VariablesVaccine Acceptance
(Urban Area)
Vaccine Acceptance
(Rural Area)
%(n/N)p-Value, OR (95% CI)%(n/N) p-Value, OR (95% CI)
Age
<3040.00(168/420)Ref34.94(109/312)Ref
[30.0–40.0]47.11(57/121)0.16, 0.34 (0.89–2.01)31.46(28/89)0.54, 0.85 (0.52–1.42)
>4050.00(35/70) 0.11, 0.50 (0.90–2.49)24.39(10/41) 0.18, 0.60 (0.28–1.27)
Marital status
Single39.41(147/373) Ref31.77(88/277) Ref
Married 44.69(101/226) 0.20, 1.24 (0.89–1.74)36.42(59/162) 0.32, 1.23 (0.82–1.85)
Sex
Féminin41.81(217/519) Ref33.69(126/374) Ref
Masculin46.74(43/92) 0.37, 1.22 (0.78–1.91)30.88(21/68)0.65, 0.88 (0.50–1.54)
Profession
Resourceful47.66(183/384) Ref38.68(82/212) Ref
Trader32.77(39/119) 0.004, 0.54 (0.35–0.82)11.49(10/87) <0.000, 0.21 (0.10–0.42)
Student41.67(10/24) 0.57, 0.78 (0.34–1.81)45.31(29/64) 0.34, 0.61 (0.31–0.752)
Others33.33(28/84) 0.058, 0.55 (0.33–0.90)32.91(26/79) 0.3657, 0.78 (0.45–1.34)
Level of education
None43.75(28/64) Ref23.57(37/157) Ref
Primary35.06(95/271) 0.19, 0.69 (0.40–1.21)42.24(73/165) 0.1522, 1.54 (0.85–2.77)
Secondary46.46(46/99) 0.73, 0.12 (0.59–2.10)27.78(10/36) 0.5960, 1.25 (0.55–2.82)
Superior51.41(91/177) 0.29, 1.36 (0.77–2.42)32.14(27/84) 0.0001, 2.57 (1.59–4.16)
Table 5. Factors to acceptance of the vaccine against COVID-19 in a multivariate regression analysis.
Table 5. Factors to acceptance of the vaccine against COVID-19 in a multivariate regression analysis.
VariablesVaccine Acceptance (Rural Area)
%(n/N) p-ValueAdjusted OR (95% CI)
Profession
Resourceful38.68(82/212) RefRef
Trader11.49(10/87) 0.00020.23(0.11–0.50)
Student45.31(29/64) 0.571.18(0.66–2.10)
Others32.91(26/79) 0.230.71(0.40–1.24)
Level of education
None23.57(37/157) RefRef
Primary42.24(73/165) 0.411.30(0.70–2.42)
Secondary27.78(10/36) 0.221.72(0.72–4.12)
Superior32.14(27/84) 0.01671.87(1.12–3.13)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Djuikoue, C.I.; Kamga Wouambo, R.; Pahane, M.M.; Demanou Fenkeng, B.; Seugnou Nana, C.; Djamfa Nzenya, J.; Fotso Kamgne, F.; Ngalani Toutcho, C.; Thumamo Pokam, B.D.; Apalata, T. Epidemiology of the Acceptance of Anti COVID-19 Vaccine in Urban and Rural Settings in Cameroon. Vaccines 2023, 11, 625. https://doi.org/10.3390/vaccines11030625

AMA Style

Djuikoue CI, Kamga Wouambo R, Pahane MM, Demanou Fenkeng B, Seugnou Nana C, Djamfa Nzenya J, Fotso Kamgne F, Ngalani Toutcho C, Thumamo Pokam BD, Apalata T. Epidemiology of the Acceptance of Anti COVID-19 Vaccine in Urban and Rural Settings in Cameroon. Vaccines. 2023; 11(3):625. https://doi.org/10.3390/vaccines11030625

Chicago/Turabian Style

Djuikoue, Cecile Ingrid, Rodrigue Kamga Wouambo, Majeste Mbiada Pahane, Blaise Demanou Fenkeng, Cedric Seugnou Nana, Joelle Djamfa Nzenya, Flore Fotso Kamgne, Cedric Ngalani Toutcho, Benjamin D. Thumamo Pokam, and Teke Apalata. 2023. "Epidemiology of the Acceptance of Anti COVID-19 Vaccine in Urban and Rural Settings in Cameroon" Vaccines 11, no. 3: 625. https://doi.org/10.3390/vaccines11030625

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop